)
Company Research29 Mar 2024
Companies That Had Their IPO in 1992: A Cautiously Optimistic Market
1992 marked a relatively cool IPO landscape and stock market sentiment, in the wake of the early 90s recession.
Boston Scientific
Boston Scientific (BSX) investor relations material
Boston Scientific M&A announcement summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.M&A announcement summary15 Jan, 2026
Deal rationale and strategic fit
Acquisition enables entry into high-growth segments like mechanical thrombectomy, embolization, and neurovascular, expanding the cardiovascular portfolio and addressing vascular diseases.
Strong cultural alignment, shared focus on innovation, and high performance, with both companies combining from positions of strength.
Expands access for more physicians and patients by leveraging global supply chain, commercial footprint, and relationships.
Penumbra brings a profitable growth profile, experienced team, and best-in-class portfolio with significant growth potential.
Strengthens position in fast-growing vascular segments with differentiated devices for stroke, pulmonary embolism, and acute limb ischemia.
Financial terms and conditions
Total consideration is $15 billion, with $374 per share in cash and stock (73% cash, 27% stock); shareholders can elect cash or stock, subject to proration.
Funded by approximately $11 billion in cash and $4 billion in stock, with about 41 million shares issued, fixed at signing based on 10-day VWAP ending January 13, 2026.
Cash portion to be financed with cash on hand and new debt; nature of debt to be finalized before closing.
The deal is expected to close in 2026, subject to shareholder and regulatory approvals and customary closing conditions.
The transaction is expected to be $0.06-0.08 dilutive to adjusted EPS in the first year, neutral to slightly accretive in year two, and increasingly accretive after full realization of synergies in year three.
Synergies and expected cost savings
Over $200 million of operating income impact from revenue synergies and cost efficiencies expected in year three.
Revenue acceleration anticipated, especially outside the U.S., leveraging the acquirer's global footprint.
Cost efficiencies expected in G&A and operations, with Penumbra operating essentially standalone post-integration.
Combination expected to deliver meaningful revenue contribution and cost efficiencies, supporting long-range planning goals.
Anticipated to enhance revenue and margins over time by leveraging proven offerings and expanding access to novel technologies.
What drives the EPS accretion timeline?
Assess competitive landscape in neurovascular.
How will global access for Penumbra products expand?
How to ensure Penumbra's innovation speed post-deal?
Reconcile Y1 EPS dilution with LRP targets.
Detail Penumbra's WAMGR acceleration for BSC.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Boston Scientific earnings date
Q4 20254 Feb, 2026
Boston Scientific
Next Boston Scientific earnings date
Q4 20254 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Boston Scientific Corporation designs, develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company's products include heart valves, falls prevention and mobility solutions, peripheral intervention devices, endovascular systems and services, and electrophysiology products. The company also provides a range of minimally invasive surgical procedures based on its innovative tissue acquisition technologies to expand the therapeutic applications for new drug therapies for gastrointestinal tract disorders. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage